Recently, ImmunoACT, supported by IIT-B and Laurus Labs, has obtained approval from India's Central Drugs Standard Control Organisation (CDSCO) for its first CAR-T cell therapy, NexCAR19 (Actalycabtagene autoleucel). This treatment targets relapsed/refractory B-cell lymphomas and leukemia.

  • NexCAR19 is an indigenous product, representing a significant leap in advanced cell-and-gene therapies. It is a collaborative effort spanning a decade involving IIT-Bombay and Tata Memorial Centre (TMC).
  • NexCAR19's approval opens the door for patients in India and resource-constrained countries to access this life-saving therapy at an affordable cost.
  • It marks a significant technical achievement, positioning India among the elite nations offering CAR-T therapy.
  • ImmunoACT, incubated at IIT ....
Do You Want to Read More?
Subscribe Now

To get access to detailed content

Already a Member? Login here

Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material before the last six months of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.